Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Conti-Fine, 2006, Myasthenia gravis: past, present, and future, J. Clin. Invest., 116, 2843, 10.1172/JCI29894 Milani, 2003, T cells and cytokines in the pathogenesis of acquired myasthenia gravis, Ann. N. Y. Acad. Sci., 998, 284, 10.1196/annals.1254.032 Xu, 2001, Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells, Cell Immunol., 208, 107–4, 10.1006/cimm.2001.1777 Zhang, 1996, Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis, J. Exp. Med., 184, 349--56, 10.1084/jem.184.2.349 Tackenberg, 2007, Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis, Eur. J. Immunol., 37, 849--63, 10.1002/eji.200636449 Rosenberg, 1996, B-cell activation in vitro by helper T cells specific to region alpha 146–162 of Torpedo californica nicotinic acetylcholine receptor, J. Immunol., 157, 3192, 10.4049/jimmunol.157.7.3192 Poussin, 2002, Role of IL-5 during primary and secondary immune response to acetylcholine receptor, J. Neuroimmunol., 125, 51, 10.1016/S0165-5728(02)00030-9 Zhang, 2001, Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR, J. Neuroimmunol., 113, 10, 10.1016/S0165-5728(00)00411-2 Ostlie, 2001, Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis, J. Immunol., 166, 4853--62, 10.4049/jimmunol.166.8.4853 Deng, 2002, Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production, J. Immunol., 169, 1077–83, 10.4049/jimmunol.169.2.1077 Carrasco, 2004, LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation, Immunity, 20, 589--99, 10.1016/S1074-7613(04)00105-0 Holland, 1997, Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway, J. Biol. Chem., 272, 9108--12, 10.1074/jbc.272.14.9108 Sari, 2002, Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus, Rheumatol. Int., 21, 149, 10.1007/s00296-001-0159-6 Potocnik, 1990, Expression of activation antigens on T cells in rheumatoid arthritis patients, Scand. J. Immunol., 31, 213, 10.1111/j.1365-3083.1990.tb02762.x Kuryliszyn-Moskal, 2001, Serum autoantibodies profile and increased levels of circulating intercellular adhesion molecule-1: a reflection of the immunologically mediated systemic vasculopathy in rheumatic diseases?, Arch. Immunol. Ther. Exp. (Warsz), 49, 423 Sonnet, 1999, Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease, J. Endocrinol. Invest., 22, 430, 10.1007/BF03343586 El-Gohary, 2004, Soluble ICAM-1 in patients with chronic hepatitis C infection: a prognostic marker of disease activity, Egypt J. Immunol., 11, 109--19 Kakoulidou, 2007, Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis, J. Neuroimmunol., 185, 150, 10.1016/j.jneuroim.2007.01.007 Lesko, 2001, Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies, Annu. Rev. Pharmacol. Toxicol., 41, 347--66, 10.1146/annurev.pharmtox.41.1.347 Cannon, 1993, Measuring circulating cytokines, J. Appl. Physiol., 75, 1897--902, 10.1152/jappl.1993.75.4.1897 Thorpe, 1992, Detection and measurement of cytokines, Blood Rev., 6, 133, 10.1016/0268-960X(92)90025-L Whicher, 1990, Cytokine measurements in body fluids, Eur. Cytokine Netw., 1, 239--43 Aziz, 1998, Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures, Clin. Diagn. Lab. Immunol., 5, 755--61, 10.1128/CDLI.5.6.755-761.1998 Dinarello, 1992, ELISA kits based on monoclonal antibodies do not measure total IL-1 beta synthesis, J. Immunol. Methods, 148, 255, 10.1016/0022-1759(92)90179-W Roncarolo, 2003, Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells, Novartis Found Symp., 252, 115, 10.1002/0470871628.ch9 Grindebacke, 2004, Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season, Clin. Exp. Allergy, 34, 1364--72, 10.1111/j.1365-2222.2004.02067.x Sakaguchi, 2004, Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses, Annu. Rev. Immunol., 22, 531, 10.1146/annurev.immunol.21.120601.141122 Baecher-Allan, 2004, Human CD4+CD25+ regulatory T cells, Semin. Immunol., 16, 89, 10.1016/j.smim.2003.12.005 Suciu-Foca, 2003, Generation and function of antigen-specific suppressor and regulatory T cells, Transpl. Immunol., 11, 235--44 Najafian, 2003, Regulatory functions of CD8+CD28− T cells in an autoimmune disease model, J. Clin. Invest., 112, 1037, 10.1172/JCI17935 Suzuki, 1999, Normal regulatory alpha/beta T cells effectively eliminate abnormally activated T cells lacking the interleukin 2 receptor beta in vivo, J. Exp. Med., 190, 1561, 10.1084/jem.190.11.1561 Thompson, 2001, BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF, Science, 293, 2108--11, 10.1126/science.1061965 Ng, 2004, B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells, J. Immunol., 173, 807--17, 10.4049/jimmunol.173.2.807 Thien, 2004, Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches, Immunity, 20, 785, 10.1016/j.immuni.2004.05.010 Most, 1993, Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) in HIV-1 infection, J. Acquir. Immune Defic. Syndr., 6, 221 El-Gohary, 2004, Soluble ICAM-1 in patients with chronic hepatitis C infection: a prognostic marker of disease activity, Egypt J. Immunol., 11, 109--19 Egerer, 2000, Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus, Lupus, 9, 614--21, 10.1191/096120300678828749 Giorelli, 2002, Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a, Cell Commun. Adhes., 9, 259--72 Kraus, 2004, Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis, J. Neurol., 251, 464--2, 10.1007/s00415-004-0358-7 G. Papaccio, M.V. Latronico, A. Graziano, A. Lanza, M. Pedulla. Tacrolimus, but not cyclosporine A, significantly increases expression of ICAM-1 and IFN-gamma in the NOD mouse. J. Cell Biochem. Suppl. 2001; Suppl 36:107--6. Tesar, 2000, Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange, Blood Purif., 18, 115, 10.1159/000014434